Welcome to our dedicated page for Theravance Bioph news (Ticker: TBPH), a resource for investors and traders seeking the latest updates and insights on Theravance Bioph stock.
Theravance Biopharma, Inc. (NASDAQ: TBPH) is a biopharmaceutical company focused on organ-selective medicines for respiratory and neurologic conditions, and the TBPH news feed highlights the company’s ongoing clinical, regulatory, commercial, and corporate developments. Company communications emphasize its role in the development of YUPELRI (revefenacin) inhalation solution, an FDA-approved once-daily nebulized LAMA for the maintenance treatment of COPD, and its late-stage investigational program with ampreloxetine for symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA).
News items for Theravance Biopharma commonly cover financial results and corporate updates, including quarterly earnings releases, collaboration revenue from YUPELRI, and commentary on operating discipline and capital allocation. Investors can also follow clinical development milestones, such as completion of enrollment in the Phase 3 CYPRESS study of ampreloxetine, the conclusion of open-label study periods, and anticipated timelines for topline data.
The TBPH news stream features scientific and medical conference activity, including platform and poster presentations on ampreloxetine at meetings like the International Symposium on the Autonomic Nervous System, as well as presentations and data on YUPELRI at respiratory congresses. In addition, Theravance Biopharma announces disease education initiatives such as the "Power in the Periphery" campaign and other efforts aimed at increasing awareness and understanding of nOH due to MSA among healthcare professionals.
Investors tracking TBPH can also see announcements about investor conferences and KOL events, where management and external experts discuss unmet medical needs in MSA-related nOH, review the ampreloxetine clinical program, and outline commercial strategies. For those following Theravance Biopharma stock, this news page provides a consolidated view of the company’s operational progress, scientific outreach, and key catalysts related to its respiratory and neurologic portfolios.
Theravance Biopharma (NASDAQ: TBPH) presented analyses of its Phase 3 program for ampreloxetine, a treatment for symptomatic neurogenic orthostatic hypotension (nOH), at the International MSA Congress. The subgroup analysis from the REDWOOD 0170 study showed that Multiple System Atrophy (MSA) patients experienced meaningful improvement in nOH symptoms after 16 weeks of treatment, with symptoms remaining stable in the ampreloxetine group while worsening in the placebo group.
Key findings revealed improved functional activities in treated patients and demonstrated ampreloxetine's sustained effect on standing blood pressure. Additional analysis from Study 0169 highlighted that MSA patients had the highest nOH symptom burden despite existing treatments, emphasizing the need for better therapies. These results support the ongoing CYPRESS registrational study in nOH and MSA patients.
Theravance Biopharma (TBPH) reported its Q1 2025 financial results, highlighting strong performance across key products. YUPELRI achieved US net sales of $58.3 million, up 6% year-over-year, with notable 48% growth in hospital channel doses. TRELEGY posted global net sales of $854 million, representing a 14% increase from Q1 2024.
The company reported total revenue of $15.4 million and a net loss of $13.6 million. Quarter-end cash balance stood at $130.9 million with no debt. R&D expenses were $11.5 million, while SG&A expenses reached $18.4 million.
The CYPRESS study for ampreloxetine, targeting neurogenic orthostatic hypotension in MSA patients, is nearing completion with final patient enrollment expected by late summer. The company's Strategic Review Committee continues to evaluate alternatives to enhance shareholder value.
Theravance Biopharma (NASDAQ: TBPH) has announced upcoming presentations of analyses from their ampreloxetine Phase 3 program at the International MSA Congress in Boston, May 9-11, 2025. The analyses focus on Studies 169 and 170, supporting ampreloxetine's potential in treating neurogenic orthostatic hypotension (nOH) in multiple system atrophy (MSA) patients.
The presentations include a plenary oral session and poster sessions featuring:
- A pre-specified subgroup analysis of a phase 3 trial by Norcliffe-Kaufmann L, et al.
- Analysis of symptomatic nOH impact on symptom burden by Iodice V, et al.
These analyses support the ongoing CYPRESS registrational study (NCT05696717) in patients with nOH and MSA, demonstrating the company's commitment to understanding ampreloxetine's selective mechanism of action.
Theravance Biopharma (NASDAQ: TBPH) has scheduled its first quarter 2025 financial results announcement and business update for Thursday, May 8, 2025, after market close. The company will host a conference call and simultaneous webcast at 5:00 pm EDT (2:00 pm PDT/10:00 pm IST) on the same day.
Participants can join via telephone by dialing (800) 715-9871 from the US or (646) 307-1963 internationally, using Conference ID 3369474. The webcast will be accessible through the Investors section of Theravance Biopharma's website and will remain available for replay until June 7, 2025.
Theravance Biopharma (NASDAQ: TBPH) presented new analyses of ampreloxetine, their investigational treatment for symptomatic neurogenic orthostatic hypotension (nOH), at the American Academy of Neurology 2025 Annual Meeting. The analyses from Phase 3 trials demonstrated the drug's selective mechanism and safety profile.
Key findings showed that patients on ampreloxetine experienced a 58% mean increase in venous plasma norepinephrine levels after 4 weeks, with MSA patients showing a 79% increase. The drug demonstrated sustained improvement in orthostatic blood pressure, particularly in MSA patients. Importantly, ampreloxetine showed no worsening of supine hypertension, a common side effect of current FDA-approved treatments that typically carry black-box warnings.
The data came from two Phase 3 trials (Study 0169 and 0170) involving patients with nOH in multiple system atrophy, Parkinson's Disease, and pure autonomic failure. These results support an ongoing registrational study (CYPRESS) in patients with nOH and MSA.
Theravance Biopharma (NASDAQ: TBPH) has announced its participation in the upcoming Jones Healthcare and Technology Innovation Conference in Las Vegas. The company will engage in a fireside chat on Wednesday, April 9 at 11:30 am PDT (2:30 pm EDT/6:30 PM GMT).
The company's senior management team will be available for one-on-one meetings during the conference. Interested parties can arrange meetings through their Jones representative or by contacting Yuki Gonzalez, Vice President of Marketing & Corporate Access.
A recording of the fireside chat will be made available on Theravance.com under the Investors section, Events and Presentations, and will remain accessible for 30 days following the event.
Theravance Biopharma (NASDAQ: TBPH) has announced new analyses of their Phase 3 ampreloxetine program for Neurogenic Orthostatic Hypotension (nOH) to be presented at the 77th Annual Meeting of the American Academy of Neurology (AAN) in San Diego from April 5-9, 2025.
The presentations, scheduled for April 7, 2025, will showcase findings from Studies 169 and 170, which led to the ongoing Phase 3 confirmatory CYPRESS Study 197 focusing on nOH in multiple system atrophy patients. Two key presentations will be delivered:
- NET-Inhibition with Ampreloxetine, Blood Pressure, and Catecholamines in nOH Patients
- The Impact of Ampreloxetine on Supine Hypertension: An Ambulatory Blood Pressure Monitoring Study
Theravance Biopharma (TBPH) reported strong Q4 and FY 2024 results, with YUPELRI achieving record US net sales of $66.7M in Q4 (up 10% YoY) and $238.6M for FY2024 (up 8% YoY). TRELEGY global net sales reached $3.46B in FY2024, up 26% YoY, triggering a $50M milestone payment to TBPH.
Q4 financial highlights include revenue of $18.8M from Viatris collaboration, R&D expenses of $9.5M, and SG&A expenses of $18.5M. The company ended Q4 with $88.4M in cash, excluding the $50M TRELEGY milestone received in February 2025.
For 2025 guidance, TBPH expects R&D expenses of $32-38M and SG&A expenses of $50-60M (excluding share-based compensation). The CYPRESS study for ampreloxetine remains on track to enroll its final patient by mid-2025.
Theravance Biopharma (NASDAQ: TBPH) has announced its participation in the TD Cowen 45th Annual Health Care Conference. The company's presentation is scheduled for Tuesday, March 4 at 11:50 am EST (8:50 am PST/4:50 pm GMT).
The company will engage in in-person meetings with the investment community during the conference. Investors and interested parties can access the webcast through the Investors section under Events and Presentations on Theravance.com. The webcast recording will remain available on the company's website for 30 days following the presentation.
Theravance Biopharma (NASDAQ: TBPH) has announced it will release its fourth quarter and full year 2024 financial results and business update after market close on February 26, 2025. The company will host a conference call and simultaneous webcast at 5:00 pm EST (2:00 pm PST/10:00 pm GMT) on the same day.
Interested participants can pre-register for the telephone conference call through the provided link. The webcast will be accessible through Theravance Biopharma's website under the Investors section, Events and Presentations. A replay of the webcast will remain available on the company's website for 30 days until March 28, 2025.
FAQ
What is the current stock price of Theravance Bioph (TBPH)?
What is the market cap of Theravance Bioph (TBPH)?
